As the Australian share market navigates a post-Budget environment marked by cautious spending and external pressures from U.S. inflation concerns, investors are keenly observing how these factors influence local indices. In such a climate, growth companies with high insider ownership may offer unique insights into potential resilience and alignment of interests between management and shareholders, making them noteworthy for those seeking stability amid broader market fluctuations.
Top 10 Growth Companies With High Insider Ownership In Australia
| Name |
Insider Ownership |
Earnings Growth |
|---|---|---|
| Torque Metals (ASX:TOR) |
18.5% |
94.2% |
| Starpharma Holdings (ASX:SPL) |
15.6% |
91.8% |
| SKS Technologies Group (ASX:SKS) |
28.2% |
42.1% |
| Pioneer Credit (ASX:PNC) |
19.5% |
24.3% |
| Pinnacle Investment Management Group (ASX:PNI) |
25.1% |
21.1% |
| Magnetic Resources (ASX:MAU) |
33.6% |
124.2% |
| Echo IQ (ASX:EIQ) |
19.7% |
108.7% |
| Austral Resources Australia (ASX:AR1) |
19.4% |
38.7% |
| Adveritas (ASX:AV1) |
17.9% |
108.4% |
| Advanced Energy Minerals (ASX:AEM) |
35.1% |
48.4% |
Let's uncover some gems from our specialized screener.
Clarity Pharmaceuticals
Simply Wall St Growth Rating:★★★★★★
Overview:Clarity Pharmaceuticals Ltd is a clinical stage radiopharmaceutical company focused on the research and development of oncology products in Australia and the United States, with a market cap of A$1.06 billion.
Operations:The company generates revenue from its radiopharmaceutical development segment, amounting to A$10.58 million.
Insider Ownership:13%
Clarity Pharmaceuticals, a growth-focused company, benefits from high insider ownership and is making significant strides in radiopharmaceuticals. Recent developments include a Commercial Manufacturing Agreement with Nucleus RadioPharma for 64Cu-SAR-bisPSMA, enhancing production capabilities across the US. The Co-PSMA trial showed promising results in prostate cancer detection, potentially redefining diagnostic pathways. Despite recent financial losses (A$55.63 million), Clarity's forecasted revenue growth of 62.3% annually positions it for future profitability within three years.
Clinuvel Pharmaceuticals
Simply Wall St Growth Rating:★★★★★☆
Overview:Clinuvel Pharmaceuticals Limited is a biopharmaceutical company that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders across Australia, Europe, the United States, Switzerland, and other international markets with a market cap of A$471.50 million.
Operations:The company's revenue is primarily generated from its Biopharmaceutical Sector, amounting to A$96.30 million.
Insider Ownership:10.2%
Clinuvel Pharmaceuticals is experiencing strong growth prospects, with earnings forecasted to rise 24.9% annually, outpacing the Australian market. The company trades at a significant discount to its estimated fair value and offers good relative value compared to peers. Recent regulatory progress in Europe for SCENESSE as a vitiligo treatment underscores potential future revenue streams. However, recent financial results showed decreased revenue (A$40.56 million) and net income (A$10.44 million), indicating challenges amidst growth opportunities.
Energy One
Simply Wall St Growth Rating:★★★★☆☆
Overview:Energy One Limited provides software products, outsourced operations, and advisory services to wholesale energy, environmental, and carbon trading markets in Australasia and Europe with a market cap of A$443.74 million.
Operations:The company generates revenue from the Energy Software Industry segment, amounting to A$67.01 million.
Insider Ownership:23.5%
Energy One's recent earnings report highlights robust growth, with net income rising to A$4.01 million from A$2.46 million year-over-year, driven by increased sales and revenue. Despite significant insider selling recently, the company maintains high insider ownership which can align management interests with shareholders. Earnings are projected to grow substantially at 38.9% annually, surpassing the Australian market's average growth rate of 12%. However, forecasted revenue growth of 14.8% remains below the ideal threshold for high-growth companies but still exceeds market averages.
-
Take a closer look at Energy One's potential here in our earnings growth report.
-
Upon reviewing our latest valuation report, Energy One's share price might be too optimistic.
Summing It All Up
-
Click this link to deep-dive into the 108 companies within our Fast Growing ASX Companies With High Insider Ownership screener.
-
Ready For A Different Approach? Uncover the next big thing with financially sound penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Companies discussed in this article include ASX:CU6 ASX:CUV and ASX:EOL.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
